Immunogenicity and Safety of Tetanus, Diphtheria and Mono Component Acellular Pertussis (TdaP) Vaccine in Comparison to Tetanus and Diphtheria (Td) Vaccine When Given as Booster Vaccinations to Adults

Launched by STATENS SERUM INSTITUT · Dec 16, 2009

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Healthy female or male adult of ≥ 18 years of age
• • 2. Completed primary vaccination with diphtheria (D), Tetanus (T) and whole cell pertussis (wP) vaccines in Denmark
• • 3. Signed informed consent
• • 4. Prepared to grant authorised persons access to medical records
• • 5. Likely to comply with instructions
• Exclusion Criteria:
• • 1. Congenital or acquired immunodeficiency or progressive neurologic disease
• • 2. Uncontrolled epilepsy or progressive encephalopathy
• • 3. Previous experience of serious adverse reaction(s) after vaccinations with diphtheria-, tetanus- acellular or whole cell pertussis- vaccines
• • 4. Vaccinated with any diphtheria, tetanus or pertussis toxoid containing vaccine within 5 years before inclusion
• • 5. Vaccinated with any tetanus toxoid, diphtheria toxoid or diphtheria CRM197 protein conjugated vaccine within 5 years before inclusion
• • 6. Known tetanus-, diphtheria- or pertussis disease/infection within 5 years before inclusion
• • 7. Known hypersensitivity or history of allergic reactions to any of the active or inactive constituents of the TdaP or Td vaccines
• • 8. Vaccinated with a live or inactivated vaccine within 1 month before inclusion
• • 9. Administration of immune modulating drugs (such as immunoglobulin, systemic corticosteroids, blood products, azathioprine, cyclosporine, infliximab) within 3 months before inclusion
• • 10. Administration of any investigational drug product or vaccine within 1 month before inclusion
• • 11. Females if pregnant or breastfeeding or not willing to use contraception during the trial